Log in
Enquire now
Ligandal

Ligandal

Nanomedicine company developing vaccines and therapies with cell-specific targeting.

OverviewStructured DataIssuesContributors

Contents

ligandal.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Healthcare
Healthcare
Science
Science
Medical software
Medical software
Nanotechnology
Nanotechnology
Vaccine
Vaccine
Biomedical engineering
Biomedical engineering
Consumer biotechnology
Consumer biotechnology
...
Location
San Francisco
San Francisco
Brooklyn
Brooklyn
New York City
New York City
0
B2X
B2C
B2C
B2B
B2B
0
Founder
Christian Foster
Christian Foster
0
Andre Watson
Andre Watson
AngelList URL
angel.co/ligandal
Pitchbook URL
pitchbook.com/profiles.../40754-80
Legal Name
Ligandal Inc.
Number of Employees (Ranges)
11 – 50
Email Address
Partnerships@ligandal.com
Full Address
399 Sands Street Building 303, Suite 609 Brooklyn, New York 112050
Investors
Techammer
Techammer
Social Impact Capital
Social Impact Capital
Redbeard Ventures
Redbeard Ventures
0
Kauffman Fellows Program
Kauffman Fellows Program
Jay Zaveri
Jay Zaveri
0
Social Capital (venture capital)
Social Capital (venture capital)
‌
KF20 Capital
Founded Date
2013
Total Funding Amount (USD)
4,580,000
Latest Funding Round Date
May 15, 2019
Business Model
Commerce
Latest Funding Type
Series A
Series A
Patents Assigned (Count)
1
Wellfound ID
ligandal
Technologies Used
CRISPR
CRISPR
Country
United States
United States
0

Other attributes

Company Operating Status
Active
Invested in
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.

Ligandal is a nanomedicine company using gene editing tools such as CRISPR and cell-specific targeting molecules or ligands. CEO and Founder Andre Watson is an inventor on 43 issued or pending patents for nucleic acid and protein delivery with cell-specific targeting molecules. Watson aims to enable biological systems to be programmed at will to treat disease and extend lifespan.

Ligandal’s approach for rapid vaccine prototyping and scalable vaccine development is being applied to developing a vaccine for SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic. The company designed a fully synthetic scaffold that mimics the epitopes which are bound by T-cell receptors and antibodies. The scaffold can be custom-tailored to new mutant forms of the virus. For therapeutic agents, the scaffold can serve as a targeting ligand that mimics viral entry into target diseased cells and tissues. The “mini viral” scaffolds can be synthesized in hours and rapidly scaled to 100 kg or more, and the company says that their process of peptide synthesis is much less expensive than for mRNA-based vaccines or therapies.

Ligandal is working with government resources and private groups to use their technology for SARS-CoV-2 vaccine and therapeutic development. Ligandal’s SARS-CoV-2 vaccine design includes immune-epitopic regions for T cell receptor MHC-1 and MHC-2 loading, antibody binding and ACE2 receptor binding regions in vaccine scaffolds of less than 70 amino acids. The scaffolds can serve as competitive inhibitors for ACE2 binding by the virus and are also designed to trigger the immune system to learn to fight the SAR-CoV-2 virus.

Ligandal has results which show they are able to predict binding pockets, using computer modeling and deep learning approaches, that are consistent with Cryo-EM and other high-resolution structural data. The company believes their peptide scaffold approach can be quickly tailored to new applications or mutated viral epitopic regions within days or weeks. Therapeutic agents such as silencing RNAs, CRISPR molecules and small molecule agents can be targeting to virally-infected cells using with their approach.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Gene Editing Startups Fabricate Industrial-Grade CRISPR Tools

Gail Dutton

https://www.liebertpub.com/doi/pdfplus/10.1089/gen.39.06.14

Journal

June 2019

Ligandal Proposes 'Antidote' to COVID-19 Using Robot-like Peptide Scaffolds

Gail Dutton

https://www.biospace.com/article/ligandal-proposes-antidote-to-covid-19-using-robot-like-peptide-scaffolds/

Web

April 16, 2020

References

Find more companies like Ligandal

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.